Physician profile
William A Edwards
NPI 1326052408
$8,117.71
in general payments reported to CMS, 2019-2025
42 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $714 · 2021: $1,593 · 2022: $1,267 · 2023: $1,187 · 2024: $944 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,249.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,513.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $851.04 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $677.53 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $360.58 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $356.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $349.74 | 2019-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $347.40 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.82 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $280.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $279.11 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $243.51 | 2019-2022 | |
| Pfizer INC. | $240.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $219.95 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $201.29 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.90 | 2019-2024 | Trintellix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.